Get started
Author

Kapil Rathi

Observed name: Rathi, Kapil
Institution: Jaslok Hospital
ORCID: 0009-0004-1606-5666
Observed ORCID: 0009-0004-1606-5666
OpenAlex ID: A5070821839
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2024 · Sylvia M. Lee, Omid Hamid, et al. · Clinical Cancer Research · 11
PDF
Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies
2023 · Enrique Alvarez, Kavita V. Nair, et al. · Journal of Medical Economics · 5
PDF
PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study
2024 · Nicole R. Grieselhuber, Praneeth Baratam, et al. · Blood · 4
PDF
Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival.
2024 · Yousef Zakharia, Sylvia Lee, et al. · Journal of Clinical Oncology · 2
Iron deficiency anemia management in Indian men using ferric carboxymaltose: A sub–evaluation of a multi–center real-world study
2026 · Ramesh Dargad, Kapil Rathi, et al. · Indian Journal of Forensic and Community Medicine
Disseminated Nocardia farcinica post haematopoietic stem cell transplantation: A case report
2026 · Anik Trivedi, Nayana Shah, et al. · Asian Pacific Journal of Tropical Medicine
Survival Outcomes and Safety of High-Dose Melphalan with Autologous Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study
2025 · Reetu Jain, Sunil Chopade, et al. · Clinical Lymphoma Myeloma & Leukemia
Supplementary Table S3 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
PDF
Supplementary Figure S5 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
Supplementary Table S1 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
PDF
Data from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
Supplementary Figure S4 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
Supplementary Figure S1 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
Supplementary Figure S3 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
Supplementary Figure S2 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
Supplementary Table S2 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
PDF
Supplementary Table S5 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
Supplementary Table S8 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
PDF
Supplementary Table S6 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
PDF
Supplementary Table S7 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
PDF
Supplementary Table S4 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
2025 · Sylvia M. Lee, Omid Hamid, et al.
PDF
Age-stratified prevalence of silent hypertension in newly diagnosed type 2 diabetes: a multicentre cross-sectional study with cardiovascular risk implications
2025 · Shubhashree Patil, Seema Bagri, et al. · Journal of Diabetes Metabolic Disorders & Control
699 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after progression on anti-PD-1 therapy
2023 · Sylvia Lee, Robert M Jotte, et al. · Journal for ImmunoTherapy of Cancer
PDF
Role of mean platelet volume in a patient with ischemic stroke: A cross sectional study
2022 · Sanjay Bhasme, Kapil Rathi, et al. · International Journal of Health and Clinical Research
PDF
Works count: 25
Citation count: 22
H-index: 3
I10-index: 1
Year
Topic
Type